Literature DB >> 22835502

Drug repurposing in pediatrics and pediatric hematology oncology.

Julie Blatt1, Seth J Corey.   

Abstract

Drug 'repurposing', that is, using old drugs for new indications, has been proposed as a more efficient strategy for drug development than the current standard of beginning with novel agents. In this review, we explore the scope of drug repurposing in pediatric hematology oncology and in pediatrics in general. Drugs commonly used in children were identified using the Harriet Lane Handbook (HLH) and searched in PubMed for different uses. Additional drugs were identified by searching PubMed and Google.com for 'drug repurposing' or 'drug repositioning'. Almost 10% of drugs with primary uses in pediatrics have been repurposed in pediatric hematology oncology or pediatrics. The observant clinician, pharmacologist and translational bioinformatician, as well as structural targeting, will have a role in discovering new repurposing opportunities.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22835502     DOI: 10.1016/j.drudis.2012.07.009

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  17 in total

Review 1.  Drug repurposing in oncology--patient and health systems opportunities.

Authors:  Francesco Bertolini; Vikas P Sukhatme; Gauthier Bouche
Journal:  Nat Rev Clin Oncol       Date:  2015-10-20       Impact factor: 66.675

Review 2.  Metronomics: towards personalized chemotherapy?

Authors:  Nicolas André; Manon Carré; Eddy Pasquier
Journal:  Nat Rev Clin Oncol       Date:  2014-06-10       Impact factor: 66.675

3.  Expanding the scope of drug repurposing in pediatrics: the Children's Pharmacy Collaborative.

Authors:  Julie Blatt; Sherif Farag; Seth J Corey; Zafeira Sarrimanolis; Eugene Muratov; Denis Fourches; Alexander Tropsha; William P Janzen
Journal:  Drug Discov Today       Date:  2014-08-19       Impact factor: 7.851

4.  Repositioning FDA-Approved Drugs in Combination with Epigenetic Drugs to Reprogram Colon Cancer Epigenome.

Authors:  Noël J-M Raynal; Elodie M Da Costa; Justin T Lee; Vazganush Gharibyan; Saira Ahmed; Hanghang Zhang; Takahiro Sato; Gabriel G Malouf; Jean-Pierre J Issa
Journal:  Mol Cancer Ther       Date:  2016-12-15       Impact factor: 6.261

5.  Drug-target interaction prediction by integrating chemical, genomic, functional and pharmacological data.

Authors:  Fan Yang; Jinbo Xu; Jianyang Zeng
Journal:  Pac Symp Biocomput       Date:  2014

Review 6.  Toward better drug repositioning: prioritizing and integrating existing methods into efficient pipelines.

Authors:  Guangxu Jin; Stephen T C Wong
Journal:  Drug Discov Today       Date:  2013-11-14       Impact factor: 7.851

7.  Medication Repurposing in Pediatric Patients: Teaching Old Drugs New Tricks.

Authors:  Martha M Rumore
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Jan-Feb

Review 8.  Gasotransmitters in cancer: from pathophysiology to experimental therapy.

Authors:  Csaba Szabo
Journal:  Nat Rev Drug Discov       Date:  2015-12-18       Impact factor: 84.694

Review 9.  Repurposing medicinal compounds for blood cancer treatment.

Authors:  Bronagh McCabe; Fabio Liberante; Ken I Mills
Journal:  Ann Hematol       Date:  2015-06-07       Impact factor: 3.673

10.  Anti-tumor activity of the beta-adrenergic receptor antagonist propranolol in neuroblastoma.

Authors:  Jennifer K Wolter; Nikolaus E Wolter; Alvaro Blanch; Teresa Partridge; Lynn Cheng; Daniel A Morgenstern; Monika Podkowa; David R Kaplan; Meredith S Irwin
Journal:  Oncotarget       Date:  2014-01-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.